MAPT and Alzheimer disease: PET tracers that measure Aβ burden, tau aggregation, and neuroinflammation provide remarkable insight directly into the processes underlying the pathophysiology of AD and MCI; however, the latter two have not yet been suggested for use in clinical practice.